RecruitingNCT06107062
Full-spectrum CBD, broad-spectrum CBD or placebo with therapy for cannabis use
About this title
Longitudinal Outpatient Treatment for Cannabis Use Disorder
Read the official source — NCT06107062Medication studyAges 21+United StatesAddiction
Understand this study
Who could participate?
Listed age limits: from 21 years.
- Listed locations
- BoulderSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 26, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 165
- Sponsor
- University of Colorado, Boulder
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 21 Years
- Official registry ID
- NCT06107062
- Official title
Show the full official title
Hemp-derived Cannabidiol for the Treatment of Cannabis Use Disorder: A Double-blind Placebo-controlled Randomized Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Boulder
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Colorado, Boulder, a university.
Does this study involve medication?
Yes. The study involves medication, including Cannabidiol - fsCBD, Placebo and Cannabidiol - bsCBD.
Who can participate?
Listed age limits: from 21 years.
Is this study still recruiting?
The registry lists this study as recruiting.
